Part of a two-case challenge series focused on the European healthcare system, this interactive module refines your multimodal PET interpretation and neurodegenerative disease differentiation skills. You’ll evaluate two patients with progressive and atypical neurodegenerative presentations ‒ including visuospatial impairment and behavioral changes with parkinsonian features ‒ integrating multimodal imaging findings with real-world clinical judgment.
If you have any questions or comments on the topics discussed, please share these through our Imaging Exchange.
Title: Case Challenge Europe: Multimodal PET Biomarkers in Neurodegenerative Disease Differentiation
Release date: March 20, 2026
Estimated time to complete activity: 10-15 mins
This program is intended for Imaging physicians, including Nuclear Medicine Physicians, Radiologists, Neuroradiologists, Radiology Physician Assistants, Imaging Residents. It is also suitable for Neurologists.
Following completion of this independent educational program, you will be able to:
Prof Alexander Drzezga
Chair of the Department of Nuclear Medicine
University Hospital of Cologne, Germany
Disclosures
Alexander Drzezga has received grant funding and research support from, Sofie, Novartis/AAA, and Deutsche Forschungsgesellschaft, DFG, BMBF, Juelich, Wellcome Leap, Bayer Vital, European Research Council, Invicros, Biogen, GE Healthcare; and honoraria or consulting fees from GE Healthcare, Biogen, Novartis, Lilly, Siemens Healthineers, Springer Healthcare, Lilly Deutschland, Peer View Institute for Medical Education Inc., Bayer Vital GmbH, Invicro, and International Atomic Energy Agency, Swiss Rockets.
He holds Stocks, shares or equity in Siemens Healthineers, Lantheus Holding, Structured Therapeutics, Lilly. In addition he has applied for patent for 2-Alkoxy-6-[18F]Fluoronicotinoyl substituted Lys-C(O)-Glu derivatives as efficient probes for imaging of PSMA expressing tissues (Patent No.: EP3765097A1).
He has received other financial or material support from Siemens Healthineers, Life Molecular Imaging, GE Healthcare, Eisai, Sofie, Ariceum Therapeutics, AVID.
